BIOMAT Database Logo BIOMAT Database Logo

Intravenous immunoglobulin modulates cutaneous involvement and reduces skin fibrosis in systemic sclerosis: an open-label study. 2004

Yair Levy, and Howard Amital, and Pnina Langevitz, and Francesca Nacci, and Anna Righi, and Letizia Conforti, and Sergio Generini, and Marco Matucci Cerinic, and Yehuda Shoenfeld
Sheba Medical Center, Tel Hashomer, Israel.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D005260 Female Females
D005355 Fibrosis Any pathological condition where fibrous connective tissue invades any organ, usually as a consequence of inflammation or other injury. Cirrhosis,Fibroses
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D012595 Scleroderma, Systemic A chronic multi-system disorder of CONNECTIVE TISSUE. It is characterized by SCLEROSIS in the SKIN, the LUNGS, the HEART, the GASTROINTESTINAL TRACT, the KIDNEYS, and the MUSCULOSKELETAL SYSTEM. Other important features include diseased small BLOOD VESSELS and AUTOANTIBODIES. The disorder is named for its most prominent feature (hard skin), and classified into subsets by the extent of skin thickening: LIMITED SCLERODERMA and DIFFUSE SCLERODERMA. Sclerosis, Systemic,Systemic Scleroderma,Systemic Sclerosis
D012867 Skin The outer covering of the body that protects it from the environment. It is composed of the DERMIS and the EPIDERMIS.
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor

Related Publications

Yair Levy, and Howard Amital, and Pnina Langevitz, and Francesca Nacci, and Anna Righi, and Letizia Conforti, and Sergio Generini, and Marco Matucci Cerinic, and Yehuda Shoenfeld
Brentuximab vedotin for skin involvement in refractory diffuse cutaneous systemic sclerosis, an open-label trial.
April 2024, Rheumatology (Oxford, England),
Yair Levy, and Howard Amital, and Pnina Langevitz, and Francesca Nacci, and Anna Righi, and Letizia Conforti, and Sergio Generini, and Marco Matucci Cerinic, and Yehuda Shoenfeld
Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study.
January 2010, Annals of the rheumatic diseases,
Yair Levy, and Howard Amital, and Pnina Langevitz, and Francesca Nacci, and Anna Righi, and Letizia Conforti, and Sergio Generini, and Marco Matucci Cerinic, and Yehuda Shoenfeld
An open-label pilot study of infliximab therapy in diffuse cutaneous systemic sclerosis.
September 2009, Annals of the rheumatic diseases,
Yair Levy, and Howard Amital, and Pnina Langevitz, and Francesca Nacci, and Anna Righi, and Letizia Conforti, and Sergio Generini, and Marco Matucci Cerinic, and Yehuda Shoenfeld
Stabilization of Microcirculation in Patients with Early Systemic Sclerosis with Diffuse Skin Involvement following Rituximab Treatment: An Open-label Study.
May 2016, The Journal of rheumatology,
Yair Levy, and Howard Amital, and Pnina Langevitz, and Francesca Nacci, and Anna Righi, and Letizia Conforti, and Sergio Generini, and Marco Matucci Cerinic, and Yehuda Shoenfeld
Skin involvement in early diffuse cutaneous systemic sclerosis: an unmet clinical need.
May 2022, Nature reviews. Rheumatology,
Yair Levy, and Howard Amital, and Pnina Langevitz, and Francesca Nacci, and Anna Righi, and Letizia Conforti, and Sergio Generini, and Marco Matucci Cerinic, and Yehuda Shoenfeld
Bosentan treatment for Raynauds phenomenon and skin fibrosis in patients with Systemic Sclerosis and pulmonary arterial hypertension: an open-label, observational, retrospective study.
January 2010, International journal of immunopathology and pharmacology,
Yair Levy, and Howard Amital, and Pnina Langevitz, and Francesca Nacci, and Anna Righi, and Letizia Conforti, and Sergio Generini, and Marco Matucci Cerinic, and Yehuda Shoenfeld
Effect of Sequential Intravenous Pulse Cyclophosphamide-Azathioprine in Systemic Sclerosis-Interstitial Lung Disease: An Open-Label Study.
January 2016, The Indian journal of chest diseases & allied sciences,
Yair Levy, and Howard Amital, and Pnina Langevitz, and Francesca Nacci, and Anna Righi, and Letizia Conforti, and Sergio Generini, and Marco Matucci Cerinic, and Yehuda Shoenfeld
Paquinimod reduces skin fibrosis in tight skin 1 mice, an experimental model of systemic sclerosis.
July 2016, Journal of dermatological science,
Yair Levy, and Howard Amital, and Pnina Langevitz, and Francesca Nacci, and Anna Righi, and Letizia Conforti, and Sergio Generini, and Marco Matucci Cerinic, and Yehuda Shoenfeld
An open-label study of high-dose intravenous immunoglobulin in severe childhood asthma.
May 1991, The Journal of allergy and clinical immunology,
Yair Levy, and Howard Amital, and Pnina Langevitz, and Francesca Nacci, and Anna Righi, and Letizia Conforti, and Sergio Generini, and Marco Matucci Cerinic, and Yehuda Shoenfeld
Involvement of Disabled-2 on skin fibrosis in systemic sclerosis.
July 2020, Journal of dermatological science,
Copied contents to your clipboard!